Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects

NCT01408576 is registered in ClinicalTrials.gov with UCB Pharma as lead sponsor.

NCT NCT01408576
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01408576 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicenter, Open-label, Extension Study to Assess the Safety and Tolerability of Epratuzumab Treatment in Systemic Lupus Erythematosus Subjects
Lead sponsor
UCB Pharma
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2011
Completion date
February 29, 2016
Enrollment
1,250 (actual)
Sites
228

Conditions

As the registry lists them; a condition with its own page is linked.

systemic lupus erythematosus